• Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Research and innovation
    • Quality and certifications
    • Commitment to sport
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • Cetilar Crema
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor Relations
    • INVESTOR
      • Shares study and research
      • Share capital and Shareholders
      • Financial statements
      • SDIR
      • Corporate events
      • Company presentation
      • Notice of meetings
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • Media
    • News
    • Social commitment
  • Careers
    • Work with us
    • Job offers
  • Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Research and innovation
    • Quality and certifications
    • Commitment to sport
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • Cetilar Crema
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor Relations
    • INVESTOR
      • Shares study and research
      • Share capital and Shareholders
      • Financial statements
      • SDIR
      • Corporate events
      • Company presentation
      • Notice of meetings
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • Media
    • News
    • Social commitment
  • Careers
    • Work with us
    • Job offers
  • it
  • en

22 December 2020

CETILAR® PATCH AND CETILAR® TAPE CERTIFIED CLASS 2A MEDICAL DEVICES

15 December 2020

MIDCAP INITIAL COVERAGE RESEARCH 15/12/2020

11 December 2020

BORSA ITALIANA ORDERS ADMISSION OF THE ORDINARY SHARES OF PHARMANUTRA TO TRADING ON THE MTA – STAR SEGMENT

11 December 2020

THE INFORMATION PROSPECTUS ON ADMISSION TO TRADING ON THE MTA – STAR SEGMENT HAS BEEN PUBLISHED

11 December 2020

CONSOB APPROVES THE INFORMATION PROSPECTUS FOR ADMISSION TO TRADING ON MTA – STAR SEGMENT

04 December 2020

BORSA ITALIANA DISPONE L’AMMISSIONE A QUOTAZIONE SUL MERCATO MTA DELLE AZIONI ORDINARIE DI PHARMANUTRA S.P.A.

01 December 2020

PHARMANUTRA S.P.A.: NEW DISTRIBUTION AGREEMENT FOR BRAZIL

25 November 2020

Alantra Research 11/11/2020

25 November 2020

Consolidated Financial Report 30/09/2020

18 November 2020

PHARMANUTRA S.P.A.: NEW INTERNATIONAL DISTRIBUTION AGREEMENTS

11 November 2020

PHARMANUTRA S.P.A.: REGISTRATION OF THE BRANDS CETILAR® AND SIDERAL® GRANTED IN THE USA

09 November 2020

PHARMANUTRA S.P.A.: CONSOLIDATED FINANCIAL REPORT AS AT 30TH SEPTEMBER 2020

1 2 … 6 >

PharmaNutra Spa

Registered office

Via Delle Lenze, 216/b - 56122 Pisa

Phone +39 050 7846500

Fax +39 050 7846524

Electronic billing code

SUBM70N

C.F. / P.Iva / Reg. Impr. 01679440501

Share capital € 1.123.097,70

I.V. | REA 146259

Contacts

Info
info@pharmanutra.it
Candidature
recruiting@pharmanutra.it
Commerciale
commerciale@pharmanutra.it
Investor relations
investorrelation@pharmanutra.it
Distribution
internationaldept@pharmanutra.it

NEWSLETTER

Subscribe to the Pharmanutra newsletter and you will be constantly updated on all our activities.
Read Newsletter Disclosure

Subscribe to the newsletter
Privacy policy Cookie policy General conditions Code of ethics 231 Model

© 2020 PharmaNutra SpA - All rights reserved